GlassScriptPhysician profile
Thomas James Mccabe
NPI 1043219306
$2,415.23
in general payments reported to CMS, 2019-2025
13 companies · $800 in 2025
The $800 reported for 2025 was more than what 76% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $140 · 2021: $238 · 2022: $217 · 2023: $422 · 2024: $101 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $588.74 | 2020-2023 | Puraply, Puraply Antimicrobial |
| Stryker Corporation | $406.99 | 2019-2025 | Citrefix, Viaflow, Asnis |
| Bioventus LLC | $370.85 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Mimedx Group, INC. | $310.26 | 2024-2025 | |
| Smith+Nephew, INC. | $199.54 | 2019-2023 | Collagenase Santyl, Stravix |
| Pacira Pharmaceuticals Incorporated | $115.12 | 2019 | |
| Trice Medical, INC. | $107.35 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $93.60 | 2025 | |
| Surgenex LLC | $72.17 | 2025 | Renograft, Surmatrix, Ardeograft |
| Paratek Pharmaceuticals, INC. | $56.09 | 2025 | Nuzyra |
| Sanara Medtech INC. | $43.30 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.23 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $20.99 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.